Clinical Trial Update: Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso [Phase 1]

View source ↗

Summary

Phase 1 study of CART-meso, a mesothelin-targeted CAR-T cell therapy, in patients with relapsed or chemotherapy-refractory advanced cancers, including malignant…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Malignant Mesothelioma
• Other Mesothelin-positive Tumors
• Ovarian Cancer
• Pancreatic Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• CART-meso (mesothelin-targeted CAR T-cell therapy)

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Malignant Mesothelioma, Pancreatic Cancer | Phase 1 | Status: UNKNOWN